These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17698191)

  • 21. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR.
    Kinz E; Leiherer A; Lang AH; Drexel H; Muendlein A
    Int J Lab Hematol; 2015 Apr; 37(2):217-24. PubMed ID: 24963593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods.
    Cankovic M; Whiteley L; Hawley RC; Zarbo RJ; Chitale D
    Am J Clin Pathol; 2009 Nov; 132(5):713-21. PubMed ID: 19846812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
    Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
    Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis.
    Murugesan G; Aboudola S; Szpurka H; Verbic MA; Maciejewski JP; Tubbs RR; Hsi ED
    Am J Clin Pathol; 2006 Apr; 125(4):625-33. PubMed ID: 16627272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Detection of JAK2V617F mutation in patients with myeloproliferative disorders with TaqMan-MGB probe].
    Ruan GR; Chen SS; Li LD; Liu YR; Qin YZ; Li JL; Ma X; Wang FR; Jiang Q; Jiang B; Liu KY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(34):2401-4. PubMed ID: 18036317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishing the method of chimerism monitoring after allogeneic stem cell transplantation using multiplex polymerase chain reaction amplification of short tandem repeat markers and Amelogenin.
    Sufliarska S; Minarik G; Horakova J; Bodova I; Bojtarova E; Czako B; Mistrik M; Drgona L; Demitrovicova M; Lakota J; Krivosikova M; Kovacs L
    Neoplasma; 2007; 54(5):424-30. PubMed ID: 17688372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two-round allele specific-polymerase chain reaction: a simple and highly sensitive method for JAK2V617F mutation detection.
    Kannim S; Thongnoppakhun W; Auewarakul CU
    Clin Chim Acta; 2009 Mar; 401(1-2):148-51. PubMed ID: 19135044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.
    Mesa RA
    Curr Opin Hematol; 2008 Mar; 15(2):121-6. PubMed ID: 18300758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK2 (V617F) mutation in healthy individuals.
    Passamonti F; Rumi E; Pietra D; Lazzarino M; Cazzola M
    Br J Haematol; 2007 Feb; 136(4):678-9. PubMed ID: 17223913
    [No Abstract]   [Full Text] [Related]  

  • 31. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).
    Kodali S; Chen C; Rathnasabapathy C; Wang JC
    Leuk Res; 2009 Dec; 33(12):e236-9. PubMed ID: 19625083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
    Ammatuna E; Ottone T; Zaza S; Lavorgna S; Grillo R; Curzi P; Panetta P; Federici G; Amadori S; Lo-Coco F
    Ann Hematol; 2007 May; 86(5):355-61. PubMed ID: 17285276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Automated JAK2V617F quantification using a magnetic filtration system and sequence-specific primer-single molecule fluorescence detection.
    Ohyashiki K; Hori K; Makino T; Ohyashiki JH
    Cancer Genet Cytogenet; 2007 Nov; 179(1):19-24. PubMed ID: 17981210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BsaXI/RFLP analysis of initial or selectively reamplified PCR product is unreliable in detecting the V617F mutation in JAK2.
    Shepard GC; Lawson HL; Hawkins GA; Owen J
    Int J Lab Hematol; 2011 Jun; 33(3):267-71. PubMed ID: 21118387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a quantitative real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation.
    Wolstencroft EC; Hanlon K; Harries LW; Standen GR; Sternberg A; Ellard S
    J Mol Diagn; 2007 Feb; 9(1):42-6. PubMed ID: 17251334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders.
    Ohyashiki K; Aota Y; Akahane D; Gotoh A; Ohyashiki JH
    Leukemia; 2007 May; 21(5):1097-9. PubMed ID: 17315023
    [No Abstract]   [Full Text] [Related]  

  • 37. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
    Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
    Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A tetra-primer polymerase chain reaction approach for the detection of JAK2 V617F mutation.
    Koksal V; Etlik O; Arican-Baris ST; Baris I
    Genet Test; 2007; 11(4):463-6. PubMed ID: 18294066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.
    Jovanovic JV; Ivey A; Vannucchi AM; Lippert E; Oppliger Leibundgut E; Cassinat B; Pallisgaard N; Maroc N; Hermouet S; Nickless G; Guglielmelli P; van der Reijden BA; Jansen JH; Alpermann T; Schnittger S; Bench A; Tobal K; Wilkins B; Cuthill K; McLornan D; Yeoman K; Akiki S; Bryon J; Jeffries S; Jones A; Percy MJ; Schwemmers S; Gruender A; Kelley TW; Reading S; Pancrazzi A; McMullin MF; Pahl HL; Cross NC; Harrison CN; Prchal JT; Chomienne C; Kiladjian JJ; Barbui T; Grimwade D
    Leukemia; 2013 Oct; 27(10):2032-9. PubMed ID: 23860450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.
    McClure R; Mai M; Lasho T
    Leukemia; 2006 Jan; 20(1):168-71. PubMed ID: 16270039
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.